Carregant...
A Randomized, Phase III Study of Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab Investigating EGFR FISH in Patients with Advanced Non-Small Cell Lung Cancer: SWOG S0819
BACKGROUND: EGFR antibodies have been shown to increase survival in patients with advanced non-small cell lung cancer (NSCLC), particularly with squamous cell (SC) histology. Our prior work suggested that EGFR copy number by fluorescence in-situ hybridization (FISH) identifies patients most likely t...
Guardat en:
| Publicat a: | Lancet Oncol |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5847342/ https://ncbi.nlm.nih.gov/pubmed/29169877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30694-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|